Cyclerion Therapeutics, Inc. (CYCN) Stock Overview
Explore Cyclerion Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Cyclerion Therapeutics, Inc. (CYCN)
Key Financials
Key Financials
Market Cap
15.7M
P/E Ratio
-1.95
EPS (TTM)
$-1.15
ROE
-0.88%
CYCN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Cyclerion Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CYCN on the NASDAQ shows an RSI of 94.72, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $2.21 for the NASDAQ listing.
Key metrics behind Cyclerion Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -1.95 and a market capitalization of 15.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CYCN on the NASDAQ.